Allelica
- Company typePrivate
- Founded2018
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Allelica firmographics
Firmographics- Name
- Allelica
- Legal name
- Allelica, Inc.
- Website
- https://allelica.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Allelica industry classification
Industry- Product category
- Clinical Genomics Software & Polygenic Risk Score Testing
- NAICS
- Medical and Diagnostic Laboratories (6215), Software Publishers (513210)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industries
- Population Genomics & Preventive Precision Health Programs (HLAAANAL), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Allelica is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Allelica business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations, Supply Chain
Revenue model
- Clinical Genetic Testing Services: Direct clinical genetic testing services for patients ordered through healthcare providers. Tests include PRS for cardiovascular disease, breast cancer, prostate cancer, and comprehensive AbsoluteDx panels. Revenue generated through insurance reimbursement and patient self-pay with financial assistance programs available.
- Software as a Service (SaaS) - PREDICT Module: Annual subscription software for clinical genetics laboratories and health systems to perform ancestry-informed PRS analysis and clinical-grade reporting. Available on cloud or on-premises deployment.
- Software as a Service (SaaS) - DISCOVER & VALIDATE Modules: SaaS platform for researchers to construct and validate new PRS. DISCOVER enables PRS development while VALIDATE tests predictive performance on independent datasets. Subscription-based cloud computing solution.
- Allelica Precision Server (Hardware/Software): On-premises hardware and containerized software solution for CLIA-compliant genomic analysis. Sold to clinical laboratories requiring in-house data processing capabilities.
- Corporate Wellness - cardioriskSCORE: Employee cardiovascular disease prevention program sold to employers. Includes DNA testing, risk assessment, and ongoing tracking through health assistant app. Generates savings on employee health insurance costs for employers.
- Clinical Trial Services: PRS trial stratification services for pharmaceutical and biotech companies. Helps shorten trial timelines, reduce participant numbers, and identify subpopulations who benefit most from therapies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Pay-as-you-go | Insurance reimbursement for eligible patients |
| Subscription | Annual | Software subscription for clinical labs |
| Subscription | Annual | Corporate wellness program pricing |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels8 records
Allelica product offering
Product offeringCore offering
Allelica develops and sells multi-ancestry polygenic risk score (PRS) software and clinical genomic testing services that quantify inherited risk for common diseases such as cardiovascular disease, breast cancer, prostate cancer, and diabetes. Its portfolio includes cloud and on-premises software modules (PREDICT, DISCOVER, VALIDATE, Allelica Precision Server), clinical tests (PRS testing, AbsoluteDx, Breast Risk Reveal), and a corporate wellness program (cardioriskSCORE). The platform integrates genome-wide genetic variants with clinical risk factors and EHR workflows for healthcare providers, clinical laboratories, employers, and pharma/biotech customers.
Product overview
Allelica is a precision medicine company offering a comprehensive genomic risk assessment platform. The core portfolio centers on polygenic risk score (PRS) testing — a platform of clinical tests and software modules designed to integrate genetics into clinical practice. The clinical tests include standalone PRS testing for multiple diseases (cardiovascular, cancer, diabetes), AbsoluteDx (a combined monogenic+polygenic solution), and Breast Risk Reveal (breast cancer-specific integrated assessment). The software suite comprises three SaaS modules: PREDICT for clinical genetics laboratories to generate PRS reports, DISCOVER for researchers to build new PRS, and VALIDATE for testing PRS on independent datasets. Allelica Precision Server provides on-premises CLIA-compliant deployment. The company also offers cardioriskSCORE as a workplace wellness solution. All products emphasize multi-ancestry calibration and integration with clinical workflows including EHR systems.
Differentiator
Problem solved
Functional benefit
Brands
- AbsoluteDx™: Brand name for Allelica's diagnostic products including breast cancer risk assessment tools.
- Breast Risk Reveal™
- CardioriskSCORE
- Allelica Precision Server (APS)
- PREDICT
- DISCOVER
- VALIDATE
Products and services
- PRS (Polygenic Risk Score) Clinical Testing Clinical PRS testing service that aggregates the effects of thousands to millions of genetic variants to assess individual predisposition to common diseases including cardiovascular disease, diabetes, and various cancers. Tests are validated and calibrated for people of diverse ancestry using ancestry-specific thresholds and are ordered through healthcare providers.
- AbsoluteDx Comprehensive monogenic plus polygenic clinical risk test that identifies carriers of pathogenic mutations and modulates penetrance through multi-ancestry polygenic risk scores. Combines low-coverage WGS (~3.2x coverage) with high-depth whole-exome sequencing (~96x coverage) to deliver risk assessment for breast cancer, prostate cancer, familial hypercholesterolemia, and comprehensive panels.
- Breast Risk Reveal Integrated breast cancer risk assessment combining monogenic, polygenic, and clinical data using Tyrer-Cuzick and BOADICEA v7 models to deliver comprehensive individualized breast cancer risk estimates across all ancestries.
- PREDICT Module Clinical genetics software module that integrates polygenic risk scores with clinical risk factors to provide detailed assessment of individual risk for common complex diseases. Generates PRS reports with ancestry-specific analysis, 10-year and lifetime risk of disease. Available as cloud or on-premises deployment for genetics laboratories with API integration to EHRs.
- DISCOVER Module Cloud-based PRS development module enabling researchers to construct and validate new polygenic risk scores. Runs ten PRS development algorithms in parallel (including LDPred2, SCT, PRScs, SBayesR, lassosum, SVM, and Clumping & Thresholding) to identify the best predictive model for a given disease, producing publication-ready scores with standardized metrics.
- VALIDATE Module PRS validation module enabling researchers to test the transferability and predictive power of polygenic risk scores on independent datasets. Assesses applicability of PRS to populations of diverse ancestry, addressing the lack of diversity in most published PRS research.
- Allelica Precision Server (APS) CLIA-compliant on-premises server solution for polygenic risk score, pharmacogenomics, and carrier screening analysis. Available as both hardware and containerized software. Designed for medical laboratories requiring in-lab data processing with regulatory compliance (CLIA, HIPAA) and enhanced data security without external data transfers.
- cardioriskSCORE Corporate cardiovascular disease prevention program utilizing genomics and real-world data to prevent heart disease. Combines polygenic DNA testing with traditional risk factors to identify high-risk employees, deliver personalized prevention recommendations, and generate health insurance cost savings. Includes a Health Assistant App for tracking blood pressure, cholesterol, and smoking status.
Quantifiable outcome
- 17% of high-risk employees identified that other assessments overlook
- +7 more outcomes
Companies that use Allelica
Customer profileNamed customers14 records
Segments5 records
Ideal customer profiles5 records
Allelica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability2 records
Feature8 records
Allelica partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- Mass General BrighamcoreAllelica selected as PRS testing collaborator for PROACT 3 clinical trial at Mass General Brigham. The randomized trial evaluates 500 adults using Allelica's multi-ancestry CAD PRS to measure how disclosure of genetic risk influences LDL cholesterol and cardiovascular health behaviors over 12 months. Trial led by Dr. Akl Fahed and follows NIH-funded PROACT 1 and 2 trials.
- US Department of Veterans AffairscorePartnership with VA to conduct clinical trial evaluating whether genomics-informed personalized care can lower cardiovascular event risk among veterans not currently on cholesterol-lowering medication. Trial uses Allelica's CAD PRS and pharmacogenetics testing to assess statin tolerance and personalized lipid-lowering strategies.
- Cambridge Enterprise (University of Cambridge)coreCommercial license agreement with Cambridge Enterprise to incorporate BOADICEA v7 breast cancer risk prediction model into Allelica's clinical risk assessment platform. The model integrates genetic variants, polygenic risk scores, family history, and clinical risk factors to generate quantitative breast cancer risk estimates.
- UAB Cardiogenomics ClinicminorUAB Cardiogenomics Clinic and Allelica partnership for clinical implementation study of coronary artery disease PRS. Study evaluates clinical value of PRS in real-world healthcare settings.
- Broad InstitutecorePartnership with Broad Institute for AbsoluteDx launch - comprehensive genetic test combining monogenic and polygenic risk assessments. Broad Institute collaboration provides validation and scientific credibility for the integrated testing approach.
- Thermo Fisher ScientificcoreIntegration of Allelica's bioinformatics software with Thermo Fisher Scientific's Axiom Human Genotyping Microarrays. Allows researchers to create and implement PRS for disease risk prediction. Integrated solution advances precision medicine by enabling more accessible genomic research workflows.
- SP BioMedminorPartnership for breast cancer PRS study with Taiwanese biobanks. SP BioMed and Allelica collaborate on PRS analysis using Taiwanese population data.
- Baylor College of MedicinecoreAllelica provides multi-ancestry PRS technology to Baylor College of Medicine for clinical implementation. Collaboration advances precision medicine by integrating PRS into patient care, improving risk assessment across diverse populations.
- University of SydneycoreUniversity of Sydney secured AU$1.4M grant plus AU$2M from industry and partnered with Allelica to advance heart disease prevention strategies through PRS application. Collaboration focused on cardiac polygenic risk scores research.
- InvitaecoreCollaboration with Invitae to build ancestry-informed polygenic risk score for breast cancer. Combines Invitae's genetic testing capabilities with Allelica's multi-ancestry PRS technology.
- LabcorpminorCollaboration with Labcorp to ensure polygenic and monogenic risk factors are assessed and accounted for in the patient journey through multi-ancestry PRS analysis.
- Yale School of MedicineminorYale researcher selected Allelica to expand PRS research on childhood neuropsychiatric disorders. Collaboration focused on developing PRS for psychiatric conditions using Allelica's DISCOVER platform.
Scale indicators10 records
Recent moves6 records
Expansion highlights3 records
Allelica competitors and assessment
Company assessmentDirect peers
- Genomics plc: UK-based genomics company building polygenic risk scores for common disease prediction and pharmaceutical trial stratification. Directly comparable to Allelica in PRS technology, customer base (pharma + health systems), and multi-ancestry focus.
- SOPHiA Genetics: Clinical genomics AI platform offering variant interpretation and reporting software to hospitals and labs globally. Comparable SaaS-based clinical genomics workflow, multi-modality analysis, and health system distribution model.
- BC Platforms: Genomics data and analytics platform providing PRS pipelines, genomic data management, and pharma research services. Overlaps with Allelica's DISCOVER/VALIDATE modules and pharma trial stratification offering.
- Genomic Prediction: Clinical PRS laboratory offering polygenic risk testing for multiple diseases. Directly comparable to Allelica in clinical PRS testing service and multi-ancestry validation focus.
- Color Health: Clinical genetic testing company offering hereditary cancer, cardiovascular, and pharmacogenomics tests to health systems and employers. Comparable clinical genetic testing menu, employer wellness programs, and EHR-integrated ordering workflow.
Broad incumbents
- Myriad Genetics: Established genetic testing company with broad hereditary cancer, pharmacogenomic, and prenatal testing menus. Overlaps with Allelica in breast cancer risk assessment (including BOADICEA/Tyrer-Cuzick integration) but operates as a much larger incumbent with established payer relationships.
- 23andMe: Consumer genetic testing company with growing health and PRS offerings. Comparable ancestry-aware genetic reports and DTC distribution, but operates at significantly larger scale and is also a therapeutic developer.
- Tempus AI: Precision medicine data and AI platform spanning oncology, cardiology, and pharma services. Comparable in health system enterprise sales, clinical-genomic data integration, and pharma trial enablement.
- Illumina: Sequencing platform leader that has also licensed Allelica's PRS software. Comparable in genomics workflow tools for clinical and research labs, but operates as a much larger incumbent with broader portfolio beyond PRS.
Others
- Labcorp: National diagnostic laboratory partner collaborating with Allelica to incorporate multi-ancestry PRS into patient testing workflows. Serves as both a partnership channel and indirect benchmark for clinical lab scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Allelica social profiles
Digital presenceAllelica compliance and trust
Trust signalCompliance7 records
Allelica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Allelica leadership team
Management profileNumber of profiles
Profiles4 records
Allelica funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Allelica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Allelica
What does Allelica do?
Allelica develops and sells multi-ancestry polygenic risk score (PRS) software and clinical genomic testing services that quantify inherited risk for common diseases such as cardiovascular disease, breast cancer, prostate cancer, and diabetes. Its portfolio includes cloud and on-premises software modules (PREDICT, DISCOVER, VALIDATE, Allelica Precision Server), clinical tests (PRS testing, AbsoluteDx, Breast Risk Reveal), and a corporate wellness program (cardioriskSCORE). The platform integrates genome-wide genetic variants with clinical risk factors and EHR workflows for healthcare providers, clinical laboratories, employers, and pharma/biotech customers.
Is Allelica a public or private company?
Allelica is a private company. It is classified as venture growth investor backed and is currently operating.
When was Allelica founded?
Allelica was founded in 2018. It employs 11 to 50 people.
Where is Allelica based?
Allelica is headquartered in New York, United States, in the North America region.
How does Allelica make money?
Six revenue lines are on record. Clinical Genetic Testing Services are the primary driver. The others are software as a Service (SaaS) - PREDICT Module, software as a Service (SaaS) - DISCOVER & VALIDATE Modules, allelica Precision Server (Hardware/Software), corporate Wellness - cardioriskSCORE and clinical Trial Services.
Who are Allelica's main competitors?
Direct peers on record are Genomics plc, SOPHiA Genetics, BC Platforms, Genomic Prediction and Color Health. Broad incumbents are Myriad Genetics, 23andMe, Tempus AI and Illumina. Labcorp is listed as an others.
Does Allelica have an API?
No public API is recorded for Allelica.
What industry is Allelica in?
Allelica's product category is Clinical Genomics Software & Polygenic Risk Score Testing. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAANAL, Population Genomics & Preventive Precision Health Programs. Its NAICS code is 6215 and its SIC code is 2835.